Hannah Life Technologies develops direct-to-consumer, home-based fertility products aimed at helping couples conceive earlier. Its product line includes the patented twoplus Sperm Guide (medical-grade silicone sperm concentrator), the twoplus Applicator for depositing sperm at the cervical opening, and the twoplus Hormone Test that delivers detailed hormone reports. The products are designed as non-invasive complements to clinic-based procedures such as intra-uterine insemination (IUI). Co-founder Benjamin Tee said he and co-founder Prusothman Raja met through the Stanford Biodesign program and built the company after personal experience with unexplained infertility and IVF. Since launching in August 2021, Hannah Life has supplied products to over a thousand households in Singapore and the United Kingdom and reported revenue growth of over 300% quarter-over-quarter. The company previously raised seed funding from Y Combinator and continues to sell direct-to-consumer. Hannah Life developed a flexible silicone vaginal device that uses proprietary surface features and microenvironment optimization to concentrate sperm at the cervical opening and boost chances of conception without clinic visits or drugs. The founders, Prusothman Sinaraja and Dr. Benjamin Tee, met as Stanford Biodesign Fellows and built the product after personal experience with infertility and invasive treatments. The device is drug-free, intended for monthly at-home use, and the company says it aims to offer pricing at roughly one-tenth the cost of an IUI cycle. The product is currently in closed beta with early positive feedback and an anecdotal report of immediate pregnancy from a Y Combinator partner. Hannah Life plans a Q1 2021 launch of its first product and expects to release 2–3 additional products during the year while pursuing distribution through clinics, retail, pharmacies, and potential employer benefits. The team positions the suite as complementary to existing fertility treatments and as a more affordable, private option for couples seeking to increase conception odds.

Total raised

$7M

Funding rounds

2

Latest round

Series A

Latest activity

May 2022